Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids

Treatment of type I gastric neuroendocrine tumors with somatostatin analogs

(2010) Mehnaaz Sultan Khuroo et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia

(2010) Constantin S. Jianu et al.   TUMOR BIOLOGY

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint

(2009) Helge L. Waldum et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs

(2008) D Campana et al.   ENDOCRINE-RELATED CANCER

Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours

(2008) Simona Grozinsky-Glasberg et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY